Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Endocrinol Diabetes Metab · 2025 · PMC12640882 · PMID 41276951

Europe PMC DOI

hedged sentence

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significancep = 0.27not close (p > 0.1)

3.3.4 Nonfatal Myocardial Infarction Semaglutide group was less likely to develop nonfatal myocardial infarction when compared to placebo, but this difference did not reach statistical significance (RR: 0.86; 95% CI: 0.66 to 1.12; p = 0.27; I 2 = 24%) (Figure 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.